Market Chatter: Novo Nordisk CEO Poised to Take Risks in Weight-Loss Rivalry

MT Newswires Live

Oct 09, 2025

Novo Nordisk (NVO) Chief Executive Officer Mike Doustdar said he is poised to face calculated risks on acquisitions to stay competitive and regain market share in weight-loss treatment, Bloomberg News reported Thursday, citing an interview.

"You need to be able to have an eye on who else is out there, who has possibly invented something above and beyond what we could do," Doustdar said, according to the report.

The company can't "shy away in taking some additional risks," the CEO said, according to the report.

On Thursday, Novo agreed to buy Akero Therapeutics (AKRO) for up to $5.2 billion in cash.

Novo didn't immediately reply to a request for comment from MT Newswires.

Novo shares fell 1.3% in recent Thursday trading, and Akero jumped 17%.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 58.82, Change: -0.79, Percent Change: -1.33

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2574164139"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2574164139\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2574164139?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-09 23:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574164139","market":"us","top_or_hot":-1,"title":"Market Chatter: Novo Nordisk CEO Poised to Take Risks in Weight-Loss Rivalry","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> (NVO) Chief Executive Officer Mike Doustdar said he is poised to face calculated risks on acquisitions to stay competitive and regain market share in weight-loss treatment, Bloomberg News reported Thursday, citing an interview.</p><p>\"You need to be able to have an eye on who else is out there, who has possibly invented something above and beyond what we could do,\" Doustdar said, according to the report.</p><p>The company can't \"shy away in taking some additional risks,\" the CEO said, according to the report.</p><p>On Thursday, Novo agreed to buy <a href=\"https://laohu8.com/S/AKRO\">Akero Therapeutics</a> (AKRO) for up to $5.2 billion in cash.</p><p>Novo didn't immediately reply to a request for comment from MT Newswires.</p><p>Novo shares fell 1.3% in recent Thursday trading, and Akero jumped 17%.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p><p>Price: 58.82, Change: -0.79, Percent Change: -1.33</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: Novo Nordisk CEO Poised to Take Risks in Weight-Loss Rivalry</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: Novo Nordisk CEO Poised to Take Risks in Weight-Loss Rivalry\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-09 23:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> (NVO) Chief Executive Officer Mike Doustdar said he is poised to face calculated risks on acquisitions to stay competitive and regain market share in weight-loss treatment, Bloomberg News reported Thursday, citing an interview.</p><p>\"You need to be able to have an eye on who else is out there, who has possibly invented something above and beyond what we could do,\" Doustdar said, according to the report.</p><p>The company can't \"shy away in taking some additional risks,\" the CEO said, according to the report.</p><p>On Thursday, Novo agreed to buy <a href=\"https://laohu8.com/S/AKRO\">Akero Therapeutics</a> (AKRO) for up to $5.2 billion in cash.</p><p>Novo didn't immediately reply to a request for comment from MT Newswires.</p><p>Novo shares fell 1.3% in recent Thursday trading, and Akero jumped 17%.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p><p>Price: 58.82, Change: -0.79, Percent Change: -1.33</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ1G4Q59.USD","symbol_name":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2574164139","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2574164139","pubTimestamp":1760025337,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Novo Nordisk  Chief Executive Officer Mike Doustdar said he is poised to face calculated risks on acquisitions to stay competitive and regain market share in weight-loss treatment, Bloomberg News reported Thursday, citing an interview.\"You need to be able to have an eye on who else is out there, who has possibly invented something above and beyond what we could do,\" Doustdar said, according to the report.The company can't \"shy away in taking some additional risks,\" the CEO said, according to the report.On Thursday, Novo agreed to buy Akero Therapeutics  for up to $5.2 billion in cash.Novo didn't immediately reply to a request for comment from MT Newswires.Novo shares fell 1.3% in recent Thursday trading, and Akero jumped 17%.Price: 58.82, Change: -0.79, Percent Change: -1.33","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","NVO.AU":"NOVO RESOURCES CORP-CDI","BK4139":"生物科技","BK4007":"制药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","AKRO":"Akero Therapeutics","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK7104":"黄金","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","NVO":"诺和诺德"},"translate_title":"市场热议：诺和诺德首席执行官准备在减肥竞争中冒险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKRO":1,"NVO.AU":1,"NVO":1.5},"content_text":"Novo Nordisk (NVO) Chief Executive Officer Mike Doustdar said he is poised to face calculated risks on acquisitions to stay competitive and regain market share in weight-loss treatment, Bloomberg News reported Thursday, citing an interview.\"You need to be able to have an eye on who else is out there, who has possibly invented something above and beyond what we could do,\" Doustdar said, according to the report.The company can't \"shy away in taking some additional risks,\" the CEO said, according to the report.On Thursday, Novo agreed to buy Akero Therapeutics (AKRO) for up to $5.2 billion in cash.Novo didn't immediately reply to a request for comment from MT Newswires.Novo shares fell 1.3% in recent Thursday trading, and Akero jumped 17%.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: 58.82, Change: -0.79, Percent Change: -1.33","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}